Elite in Head and Neck Squamous Cell Carcinoma (HNSCC)

Dr. Jennifer M. Johnson

Jefferson University Physicians
Philadelphia, PA
Elite
in Head and Neck Squamous Cell Carcinoma (HNSCC)
Specialties:Oncology
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Jennifer Johnson is an Oncologist in Philadelphia, Pennsylvania. Dr. Johnson and is rated as an Elite provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Nasopharyngeal Carcinoma, Small Cell Lung Cancer (SCLC), Laryngeal Cancer, and Gastrostomy.

Her clinical research consists of co-authoring 70 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 28 articles and participated in 3 clinical trials in the study of Head and Neck Squamous Cell Carcinoma (HNSCC).

Specialties
Oncology
Licenses
Internal Medicine in NJ
Hospital Affiliations
Thomas Jefferson University Hospital
Main Line Hospital Lankenau
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Humana

Locations

JEFFERSON UNIVERSITY PHYSICIANS
925 Chestnut St, Suite 3, Philadelphia, PA 19107
215-955-8874

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Suspended
Publish Date: February 25, 2025
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: February 03, 2025
Intervention Type: Biological, Radiation
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
Enrollment Status: Active_not_recruiting
Publish Date: January 20, 2025
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 1/Phase 2
Nivolumab Plus Weekly Carboplatin and Paclitaxel as Induction in Resectable Locally Advanced Head and Neck Cancer
Nivolumab Plus Weekly Carboplatin and Paclitaxel as Induction in Resectable Locally Advanced Head and Neck Cancer
Enrollment Status: Completed
Publish Date: April 01, 2024
Intervention Type: Biological, Drug
Study Phase: Phase 2
An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer
An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer
Enrollment Status: Completed
Publish Date: February 28, 2024
Intervention Type: Radiation, Drug
Study Drug: MK-3475
Study Phase: Phase 1
A Pilot Study to Evaluate the Predictive Value of Circulating Tumor DNA for Clinical Outcome in Patients With Advanced Head and Neck and Lung Cancers
A Pilot Study to Evaluate the Predictive Value of Circulating Tumor DNA for Clinical Outcome in Patients With Advanced Head and Neck and Lung Cancers
Enrollment Status: Completed
Publish Date: February 16, 2024
Intervention Type: Other
A Phase 1 Open-label Study of SNX281 Given as Monotherapy and in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors and Lymphoma
A Phase 1 Open-label Study of SNX281 Given as Monotherapy and in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors and Lymphoma
Enrollment Status: Terminated
Publish Date: January 30, 2024
Intervention Type: Drug
Study Drugs: SNX281, Pembrolizumab
Study Phase: Phase 1
A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Enrollment Status: Completed
Publish Date: March 09, 2022
Intervention Type: Biological
Study Phase: Phase 1
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin
Enrollment Status: Completed
Publish Date: August 21, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Evaluation of the Addition of N-Acetylcysteine to Topotecan in the Tumor Microenvironment of Persistent or Recurrent High Grade Endometrioid or Serous Ovarian Carcinoma
Evaluation of the Addition of N-Acetylcysteine to Topotecan in the Tumor Microenvironment of Persistent or Recurrent High Grade Endometrioid or Serous Ovarian Carcinoma
Enrollment Status: Terminated
Publish Date: January 03, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials
Similar Doctors
Expertise in
33
conditions
Dr. Roger B. Cohen
Hematology Oncology | Oncology
Expertise in
33
conditions
Dr. Roger B. Cohen
Hematology Oncology | Oncology

University Of Penn - Medical Group

3400 Civic Ctr Blvd, Fl 2, 
Philadelphia, PA 
 (1.9 mi)
215-615-0063
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Roger Cohen is a Hematologist Oncology specialist and an Oncologist in Philadelphia, Pennsylvania. Dr. Cohen and is rated as an Elite provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Small Cell Lung Cancer (SCLC), and Tissue Biopsy. Dr. Cohen is currently accepting new patients.

Expertise in
4
conditions
Dr. Jonathan D. Cheng
Oncology | Transplant Surgery
Expertise in
4
conditions
Dr. Jonathan D. Cheng
Oncology | Transplant Surgery
333 Cottman Ave, Fox Chase Cancer Center, 
Philadelphia, PA 
 (9.0 mi)
215-728-6900
Languages Spoken:
English
See accepted insurances

Jonathan Cheng is an Oncologist and a Transplant Surgeon in Philadelphia, Pennsylvania. Dr. Cheng and is rated as a Distinguished provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Cancer, Familial Pancreatic Cancer, and Stomach Cancer.

Expertise in
21
conditions
Dr. Rita S. Axelrod
Oncology | Hematology
Expertise in
21
conditions
Dr. Rita S. Axelrod
Oncology | Hematology

Jefferson University Physicians

925 Chestnut St, Suite 3, 
Philadelphia, PA 
215-955-8874
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rita Axelrod is an Oncologist and a Hematologist in Philadelphia, Pennsylvania. Dr. Axelrod and is rated as a Distinguished provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Pleuropulmonary Blastoma.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile